ID   G3P_HUMAN               Reviewed;         335 AA.
AC   P04406; E7EUT4; P00354; Q53X65;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   10-MAY-2017, entry version 223.
DE   RecName: Full=Glyceraldehyde-3-phosphate dehydrogenase;
DE            Short=GAPDH;
DE            EC=1.2.1.12;
DE   AltName: Full=Peptidyl-cysteine S-nitrosylase GAPDH;
DE            EC=2.6.99.-;
GN   Name=GAPDH; Synonyms=GAPD; ORFNames=CDABP0047, OK/SW-cl.12;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=6096136;
RA   Hanauer A., Mandel J.-L.;
RT   "The glyceraldehyde 3 phosphate dehydrogenase gene family: structure
RT   of a human cDNA and of an X chromosome linked pseudogene; amazing
RT   complexity of the gene family in mouse.";
RL   EMBO J. 3:2627-2633(1984).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=6096821; DOI=10.1093/nar/12.23.9179;
RA   Arcari P., Martinelli R., Salvatore F.;
RT   "The complete sequence of a full length cDNA for human liver
RT   glyceraldehyde-3-phosphate dehydrogenase: evidence for multiple mRNA
RT   species.";
RL   Nucleic Acids Res. 12:9179-9189(1984).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=2987855; DOI=10.1093/nar/13.7.2485;
RA   Tso J.Y., Sun X.-H., Kao T.-H., Reece K.S., Wu R.;
RT   "Isolation and characterization of rat and human glyceraldehyde-3-
RT   phosphate dehydrogenase cDNAs: genomic complexity and molecular
RT   evolution of the gene.";
RL   Nucleic Acids Res. 13:2485-2502(1985).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lung;
RX   PubMed=3664468;
RA   Tokunaga K., Nakamura Y., Sakata K., Fujimori K., Ohkubo M.,
RA   Sawada K., Sakiyama S.;
RT   "Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase
RT   gene in human lung cancers.";
RL   Cancer Res. 47:5616-5619(1987).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3027061;
RA   Allen R.W., Trach K.A., Hoch J.A.;
RT   "Identification of the 37-kDa protein displaying a variable
RT   interaction with the erythroid cell membrane as glyceraldehyde-3-
RT   phosphate dehydrogenase.";
RL   J. Biol. Chem. 262:649-653(1987).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=3170585;
RA   Ercolani L., Florence B., Denaro M., Alexander M.;
RT   "Isolation and complete sequence of a functional human glyceraldehyde-
RT   3-phosphate dehydrogenase gene.";
RL   J. Biol. Chem. 263:15335-15341(1988).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RX   PubMed=1924305; DOI=10.1073/pnas.88.19.8460;
RA   Meyer-Siegler K., Mauro D.J., Seal G., Wurzer J., Deriel J.K.,
RA   Sirover M.A.;
RT   "A human nuclear uracil DNA glycosylase is the 37-kDa subunit of
RT   glyceraldehyde-3-phosphate dehydrogenase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:8460-8464(1991).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Astrocytoma;
RX   PubMed=10944468; DOI=10.1006/bbrc.2000.3282;
RA   Ye Z., Connor J.R.;
RT   "cDNA cloning by amplification of circularized first strand cDNAs
RT   reveals non-IRE-regulated iron-responsive mRNAs.";
RL   Biochem. Biophys. Res. Commun. 275:223-227(2000).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Leukemia;
RA   Zhou J., Yu W., Tang H., Mei G., Tsang Y.T.M., Bouck J., Gibbs R.A.,
RA   Margolin J.F.;
RT   "Pediatric leukemia cDNA sequencing project.";
RL   Submitted (JUL-2000) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Colon adenocarcinoma;
RA   Shichijo S., Itoh K.;
RT   "Identification of immuno-peptidmics that are recognized by tumor-
RT   reactive CTL generated from TIL of colon cancer patients.";
RL   Submitted (MAY-2001) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLY-22.
RG   NIEHS SNPs program;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [16]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Eye, Kidney, Lung, Lymph, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [17]
RP   PRELIMINARY PROTEIN SEQUENCE OF 2-335.
RC   TISSUE=Muscle;
RX   PubMed=7030790; DOI=10.1016/0014-5793(81)80587-X;
RA   Nowak K., Wolny M., Banas T.;
RT   "The complete amino acid sequence of human muscle glyceraldehyde 3-
RT   phosphate dehydrogenase.";
RL   FEBS Lett. 134:143-146(1981).
RN   [18]
RP   PROTEIN SEQUENCE OF 2-13.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [19]
RP   PROTEIN SEQUENCE OF 2-13; 62-84; 118-139; 198-215; 220-227; 235-248
RP   AND 310-335, CLEAVAGE OF INITIATOR METHIONINE, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RC   TISSUE=Prostatic carcinoma;
RA   Bienvenut W.V., Gao M., Leug H.;
RL   Submitted (JUL-2009) to UniProtKB.
RN   [20]
RP   PROTEIN SEQUENCE OF 67-80; 87-107; 119-139; 146-186; 201-215; 235-248
RP   AND 310-334, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Vishwanath V., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [21]
RP   PROTEIN SEQUENCE OF 220-226 AND 242-246.
RC   TISSUE=Heart;
RX   PubMed=7498159; DOI=10.1002/elps.11501601192;
RA   Kovalyov L.I., Shishkin S.S., Efimochkin A.S., Kovalyova M.A.,
RA   Ershova E.S., Egorov T.A., Musalyamov A.K.;
RT   "The major protein expression profile and two-dimensional protein
RT   database of human heart.";
RL   Electrophoresis 16:1160-1169(1995).
RN   [22]
RP   PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Muscle;
RX   PubMed=1193541;
RA   Nowak K., Kuczek M., Ostropolska L., Malarska A., Wolny M.,
RA   Branowski T.;
RT   "The covalent structure of glyceraldehyde-phosphate dehydrogenase from
RT   human muscles. Isolation and amino acid sequences of peptides from
RT   tryptic digest.";
RL   Hoppe-Seyler's Z. Physiol. Chem. 356:1181-1183(1975).
RN   [23]
RP   FUNCTION, AND INTERACTION WITH PRKCI.
RX   PubMed=11724794; DOI=10.1074/jbc.M109744200;
RA   Tisdale E.J.;
RT   "Glyceraldehyde-3-phosphate dehydrogenase is phosphorylated by protein
RT   kinase Ciota /lambda and plays a role in microtubule dynamics in the
RT   early secretory pathway.";
RL   J. Biol. Chem. 277:3334-3341(2002).
RN   [24]
RP   SUBCELLULAR LOCATION.
RX   PubMed=12829261; DOI=10.1016/S0304-4165(03)00117-X;
RA   Mazzola J.L., Sirover M.A.;
RT   "Subcellular localization of human glyceraldehyde-3-phosphate
RT   dehydrogenase is independent of its glycolytic function.";
RL   Biochim. Biophys. Acta 1622:50-56(2003).
RN   [25]
RP   IDENTIFICATION IN THE GAIT COMPLEX.
RX   PubMed=15479637; DOI=10.1016/j.cell.2004.09.030;
RA   Sampath P., Mazumder B., Seshadri V., Gerber C.A., Chavatte L.,
RA   Kinter M., Ting S.M., Dignam J.D., Kim S., Driscoll D.M., Fox P.L.;
RT   "Noncanonical function of glutamyl-prolyl-tRNA synthetase: gene-
RT   specific silencing of translation.";
RL   Cell 119:195-208(2004).
RN   [26]
RP   INTERACTION WITH WARS.
RX   PubMed=15628863; DOI=10.1021/bi048313k;
RA   Wakasugi K., Nakano T., Morishima I.;
RT   "Oxidative stress-responsive intracellular regulation specific for the
RT   angiostatic form of human tryptophanyl-tRNA synthetase.";
RL   Biochemistry 44:225-232(2005).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-42, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [29]
RP   INTERACTION WITH USP25.
RX   PubMed=16501887; DOI=10.1007/s00018-005-5533-1;
RA   Bosch-Comas A., Lindsten K., Gonzalez-Duarte R., Masucci M.G.,
RA   Marfany G.;
RT   "The ubiquitin-specific protease USP25 interacts with three sarcomeric
RT   proteins.";
RL   Cell. Mol. Life Sci. 63:723-734(2006).
RN   [30]
RP   ISGYLATION.
RX   PubMed=16815975; DOI=10.1073/pnas.0600397103;
RA   Wong J.J., Pung Y.F., Sze N.S., Chin K.C.;
RT   "HERC5 is an IFN-induced HECT-type E3 protein ligase that mediates
RT   type I IFN-induced ISGylation of protein targets.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:10735-10740(2006).
RN   [31]
RP   PHOSPHORYLATION AT THR-75; SER-122; SER-148; THR-229; THR-237 AND
RP   SER-312, DEAMIDATION AT ASN-9; ASN-64; ASN-70; ASN-149; ASN-155;
RP   ASN-225 AND ASN-316, AND METHYLATION AT LYS-5; LYS-66; LYS-194;
RP   LYS-215; LYS-227; LYS-260; LYS-263 AND LYS-334.
RX   PubMed=18183946; DOI=10.1021/pr700657y;
RA   Seo J., Jeong J., Kim Y.M., Hwang N., Paek E., Lee K.-J.;
RT   "Strategy for comprehensive identification of post-translational
RT   modifications in cellular proteins, including low abundant
RT   modifications: application to glyceraldehyde-3-phosphate
RT   dehydrogenase.";
RL   J. Proteome Res. 7:587-602(2008).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83; SER-151 AND THR-184,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [34]
RP   INTERACTION WITH FKBP6.
RX   PubMed=19001379; DOI=10.1074/jbc.M709779200;
RA   Jarczowski F., Jahreis G., Erdmann F., Schierhorn A., Fischer G.,
RA   Edlich F.;
RT   "FKBP36 is an inherent multifunctional glyceraldehyde-3-phosphate
RT   dehydrogenase inhibitor.";
RL   J. Biol. Chem. 284:766-773(2009).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-184; THR-211 AND
RP   SER-312, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [36]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-61; LYS-194; LYS-219;
RP   LYS-227 AND LYS-254, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [37]
RP   INTERACTION WITH EIF1AD.
RX   PubMed=20644585; DOI=10.1134/S1068162010030027;
RA   Rakitina T.V., Bogatova O.V., Smirnova E.V., Pozdeev V.I.,
RA   Kostanian I.A., Lipkin V.M.;
RT   "Haponin (eIF1AD) interacts with glyceraldehyde 3-phosphate
RT   dehydrogenase in the CHO-K1 cell line.";
RL   Bioorg. Khim. 36:312-318(2010).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-75; SER-83 AND THR-184,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [39]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [40]
RP   MALONYLATION AT LYS-194 AND LYS-215.
RX   PubMed=21908771; DOI=10.1074/mcp.M111.012658;
RA   Peng C., Lu Z., Xie Z., Cheng Z., Chen Y., Tan M., Luo H., Zhang Y.,
RA   He W., Yang K., Zwaans B.M., Tishkoff D., Ho L., Lombard D., He T.C.,
RA   Dai J., Verdin E., Ye Y., Zhao Y.;
RT   "The first identification of lysine malonylation substrates and its
RT   regulatory enzyme.";
RL   Mol. Cell. Proteomics 10:M111.012658.01-M111.012658.12(2011).
RN   [41]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [42]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22905912; DOI=10.1021/pr300539b;
RA   Rosenow A., Noben J.P., Jocken J., Kallendrusch S.,
RA   Fischer-Posovszky P., Mariman E.C., Renes J.;
RT   "Resveratrol-induced changes of the human adipocyte secretion
RT   profile.";
RL   J. Proteome Res. 11:4733-4743(2012).
RN   [43]
RP   INTERACTION WITH RPL13A, AND S-NITROSYLATION AT CYS-247.
RX   PubMed=22771119; DOI=10.1016/j.molcel.2012.06.006;
RA   Jia J., Arif A., Willard B., Smith J.D., Stuehr D.J., Hazen S.L.,
RA   Fox P.L.;
RT   "Protection of extraribosomal RPL13a by GAPDH and dysregulation by S-
RT   nitrosylation.";
RL   Mol. Cell 47:656-663(2012).
RN   [44]
RP   FUNCTION, AND RECONSTITUTION OF THE GAIT COMPLEX.
RX   PubMed=23071094; DOI=10.1128/MCB.01168-12;
RA   Arif A., Chatterjee P., Moodt R.A., Fox P.L.;
RT   "Heterotrimeric GAIT complex drives transcript-selective translation
RT   inhibition in murine macrophages.";
RL   Mol. Cell. Biol. 32:5046-5055(2012).
RN   [45]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [46]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83; SER-151; THR-153;
RP   THR-229 AND SER-333, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [47]
RP   S-NITROSYLATION AT CYS-247, MUTAGENESIS OF LEU-245 AND GLU-250, AND
RP   DOMAIN.
RX   PubMed=25417112; DOI=10.1016/j.cell.2014.09.032;
RA   Jia J., Arif A., Terenzi F., Willard B., Plow E.F., Hazen S.L.,
RA   Fox P.L.;
RT   "Target-selective protein S-nitrosylation by sequence motif
RT   recognition.";
RL   Cell 159:623-634(2014).
RN   [48]
RP   MECHANISM OF FREE RADICAL-INDUCED AGGREGATION, OXIDATION AT MET-46,
RP   AND MUTAGENESIS OF MET-46; MET-105; CYS-152; CYS-156; TRP-196; CYS-247
RP   AND TYR-320.
RX   PubMed=25086035; DOI=10.1074/jbc.M114.570275;
RA   Samson A.L., Knaupp A.S., Kass I., Kleifeld O., Marijanovic E.M.,
RA   Hughes V.A., Lupton C.J., Buckle A.M., Bottomley S.P., Medcalf R.L.;
RT   "Oxidation of an exposed methionine instigates the aggregation of
RT   glyceraldehyde-3-phosphate dehydrogenase.";
RL   J. Biol. Chem. 289:26922-26936(2014).
RN   [49]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-177; THR-182; THR-184
RP   AND SER-241, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [50]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (3.5 ANGSTROMS).
RX   PubMed=957435; DOI=10.1016/0022-2836(76)90013-9;
RA   Mercer W.D., Winn S.I., Watson H.C.;
RT   "Twinning in crystals of human skeletal muscle D-glyceraldehyde-3-
RT   phosphate dehydrogenase.";
RL   J. Mol. Biol. 104:277-283(1976).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) IN COMPLEX WITH NAD, AND
RP   SUBUNIT.
RX   PubMed=16239728; DOI=10.1107/S0907444905026740;
RA   Ismail S.A., Park H.W.;
RT   "Structural analysis of human liver glyceraldehyde-3-phosphate
RT   dehydrogenase.";
RL   Acta Crystallogr. D 61:1508-1513(2005).
RN   [53]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) IN COMPLEX WITH NAD, AND
RP   SUBUNIT.
RX   PubMed=16510976; DOI=10.1107/S0907444905042289;
RA   Jenkins J.L., Tanner J.J.;
RT   "High-resolution structure of human D-glyceraldehyde-3-phosphate
RT   dehydrogenase.";
RL   Acta Crystallogr. D 62:290-301(2006).
CC   -!- FUNCTION: Has both glyceraldehyde-3-phosphate dehydrogenase and
CC       nitrosylase activities, thereby playing a role in glycolysis and
CC       nuclear functions, respectively. Participates in nuclear events
CC       including transcription, RNA transport, DNA replication and
CC       apoptosis. Nuclear functions are probably due to the nitrosylase
CC       activity that mediates cysteine S-nitrosylation of nuclear target
CC       proteins such as SIRT1, HDAC2 and PRKDC. Modulates the
CC       organization and assembly of the cytoskeleton. Facilitates the
CC       CHP1-dependent microtubule and membrane associations through its
CC       ability to stimulate the binding of CHP1 to microtubules (By
CC       similarity). Glyceraldehyde-3-phosphate dehydrogenase is a key
CC       enzyme in glycolysis that catalyzes the first step of the pathway
CC       by converting D-glyceraldehyde 3-phosphate (G3P) into 3-phospho-D-
CC       glyceroyl phosphate. Component of the GAIT (gamma interferon-
CC       activated inhibitor of translation) complex which mediates
CC       interferon-gamma-induced transcript-selective translation
CC       inhibition in inflammation processes. Upon interferon-gamma
CC       treatment assembles into the GAIT complex which binds to stem
CC       loop-containing GAIT elements in the 3'-UTR of diverse
CC       inflammatory mRNAs (such as ceruplasmin) and suppresses their
CC       translation. {ECO:0000250, ECO:0000269|PubMed:11724794,
CC       ECO:0000269|PubMed:23071094, ECO:0000269|PubMed:3170585}.
CC   -!- CATALYTIC ACTIVITY: D-glyceraldehyde 3-phosphate + phosphate +
CC       NAD(+) = 3-phospho-D-glyceroyl phosphate + NADH.
CC       {ECO:0000255|PROSITE-ProRule:PRU10009,
CC       ECO:0000269|PubMed:3170585}.
CC   -!- PATHWAY: Carbohydrate degradation; glycolysis; pyruvate from D-
CC       glyceraldehyde 3-phosphate: step 1/5.
CC   -!- SUBUNIT: Homotetramer. Interacts with TPPP; the interaction is
CC       direct. Interacts (when S-nitrosylated) with SIAH1; leading to
CC       nuclear translocation. Interacts with RILPL1/GOSPEL, leading to
CC       prevent the interaction between GAPDH and SIAH1 and prevent
CC       nuclear translocation. Interacts with CHP1; the interaction
CC       increases the binding of CHP1 with microtubules. Associates with
CC       microtubules (By similarity). Interacts with EIF1AD, USP25, PRKCI
CC       and WARS. Interacts with phosphorylated RPL13A; inhibited by
CC       oxidatively-modified low-densitity lipoprotein (LDL(ox)).
CC       Component of the GAIT complex. Interacts with FKBP6; leading to
CC       inhibit GAPDH catalytic activity. {ECO:0000250,
CC       ECO:0000269|PubMed:11724794, ECO:0000269|PubMed:15479637,
CC       ECO:0000269|PubMed:15628863, ECO:0000269|PubMed:16239728,
CC       ECO:0000269|PubMed:16501887, ECO:0000269|PubMed:16510976,
CC       ECO:0000269|PubMed:19001379, ECO:0000269|PubMed:20644585,
CC       ECO:0000269|PubMed:22771119}.
CC   -!- INTERACTION:
CC       Self; NbExp=2; IntAct=EBI-354056, EBI-354056;
CC       Q60823:Akt2 (xeno); NbExp=2; IntAct=EBI-354056, EBI-400263;
CC       P00533:EGFR; NbExp=6; IntAct=EBI-354056, EBI-297353;
CC       P35228:NOS2; NbExp=8; IntAct=EBI-354056, EBI-6662224;
CC       P12004:PCNA; NbExp=3; IntAct=EBI-354056, EBI-358311;
CC       P00558:PGK1; NbExp=2; IntAct=EBI-354056, EBI-709599;
CC       P48147:PREP; NbExp=5; IntAct=EBI-354056, EBI-1049962;
CC       P15927:RPA2; NbExp=2; IntAct=EBI-354056, EBI-621404;
CC       P05109:S100A8; NbExp=6; IntAct=EBI-354056, EBI-355281;
CC       Q9BSI4:TINF2; NbExp=2; IntAct=EBI-354056, EBI-717399;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol
CC       {ECO:0000269|PubMed:12829261}. Nucleus {ECO:0000250}. Cytoplasm,
CC       perinuclear region {ECO:0000269|PubMed:12829261}. Membrane
CC       {ECO:0000269|PubMed:12829261}. Cytoplasm, cytoskeleton
CC       {ECO:0000250}. Note=Translocates to the nucleus following S-
CC       nitrosylation and interaction with SIAH1, which contains a nuclear
CC       localization signal (By similarity). Postnuclear and Perinuclear
CC       regions. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P04406-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P04406-2; Sequence=VSP_047289;
CC         Note=No experimental confirmation available. Gene prediction
CC         based on EST data.;
CC   -!- DOMAIN: The [IL]-x-C-x-x-[DE] motif is a proposed target motif for
CC       cysteine S-nitrosylation mediated by the iNOS-S100A8/A9
CC       transnitrosylase complex. {ECO:0000305|PubMed:25417112}.
CC   -!- PTM: S-nitrosylation of Cys-152 leads to interaction with SIAH1,
CC       followed by translocation to the nucleus (By similarity). S-
CC       nitrosylation of Cys-247 is induced by interferon-gamma and
CC       LDL(ox) implicating the iNOS-S100A8/9 transnitrosylase complex and
CC       seems to prevent interaction with phosphorylated RPL13A and to
CC       interfere with GAIT complex activity.
CC       {ECO:0000250|UniProtKB:P04797, ECO:0000269|PubMed:22771119,
CC       ECO:0000269|PubMed:25417112}.
CC   -!- PTM: ISGylated. {ECO:0000305|PubMed:16815975}.
CC   -!- PTM: Sulfhydration at Cys-152 increases catalytic activity.
CC       {ECO:0000250}.
CC   -!- PTM: Oxidative stress can promote the formation of high molecular
CC       weight disulfide-linked GAPDH aggregates, through a process called
CC       nucleocytoplasmic coagulation. Such aggregates can be observed in
CC       vivo in the affected tissues of patients with Alzheimer disease or
CC       alcoholic liver cirrhosis, or in cell cultures during necrosis.
CC       Oxidation at Met-46 may play a pivotal role in the formation of
CC       these insoluble structures. This modification has been detected in
CC       vitro following treatment with free radical donor (+/-)-(E)-4-
CC       ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexenamide. It has been
CC       proposed to destabilize nearby residues, increasing the likelihood
CC       of secondary oxidative damages, including oxidation of Tyr-45 and
CC       Met-105. This cascade of oxidations may augment GAPDH misfolding,
CC       leading to intermolecular disulfide cross-linking and aggregation.
CC       {ECO:0000305|PubMed:25086035}.
CC   -!- SIMILARITY: Belongs to the glyceraldehyde-3-phosphate
CC       dehydrogenase family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/gapd/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Glyceraldehyde 3-phosphate
CC       dehydrogenase entry;
CC       URL="https://en.wikipedia.org/wiki/Glyceraldehyde_3-phosphate_dehydrogenase";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X01677; CAA25833.1; -; mRNA.
DR   EMBL; M17851; AAA86283.1; -; mRNA.
DR   EMBL; M33197; AAA52518.1; -; mRNA.
DR   EMBL; J02642; AAA52496.1; -; mRNA.
DR   EMBL; J04038; AAA53191.1; -; Genomic_DNA.
DR   EMBL; X53778; CAA37794.1; -; mRNA.
DR   EMBL; AF261085; AAF99678.1; -; mRNA.
DR   EMBL; AY007133; AAG01996.1; -; mRNA.
DR   EMBL; AB062273; BAB93466.1; -; mRNA.
DR   EMBL; BT006893; AAP35539.1; -; mRNA.
DR   EMBL; AY340484; AAP88932.1; -; Genomic_DNA.
DR   EMBL; CR407671; CAG28599.1; -; mRNA.
DR   EMBL; AC006064; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471116; EAW88787.1; -; Genomic_DNA.
DR   EMBL; BC001601; AAH01601.1; -; mRNA.
DR   EMBL; BC004109; AAH04109.1; -; mRNA.
DR   EMBL; BC009081; AAH09081.1; -; mRNA.
DR   EMBL; BC013310; AAH13310.1; -; mRNA.
DR   EMBL; BC023632; AAH23632.1; -; mRNA.
DR   EMBL; BC025925; AAH25925.1; -; mRNA.
DR   EMBL; BC026907; AAH26907.1; -; mRNA.
DR   EMBL; BC029618; AAH29618.1; -; mRNA.
DR   EMBL; BC083511; AAH83511.1; -; mRNA.
DR   CCDS; CCDS58201.1; -. [P04406-2]
DR   CCDS; CCDS8549.1; -. [P04406-1]
DR   PIR; A31988; DEHUG3.
DR   RefSeq; NP_001243728.1; NM_001256799.2. [P04406-2]
DR   RefSeq; NP_001276674.1; NM_001289745.1. [P04406-1]
DR   RefSeq; NP_001276675.1; NM_001289746.1. [P04406-1]
DR   RefSeq; NP_002037.2; NM_002046.5. [P04406-1]
DR   UniGene; Hs.544577; -.
DR   UniGene; Hs.592355; -.
DR   UniGene; Hs.598320; -.
DR   PDB; 1U8F; X-ray; 1.75 A; O/P/Q/R=1-335.
DR   PDB; 1ZNQ; X-ray; 2.50 A; O/P/Q/R=1-335.
DR   PDB; 2FEH; Model; -; O/P/Q/R=1-335.
DR   PDB; 3GPD; X-ray; 3.50 A; G/R=2-335.
DR   PDB; 4WNC; X-ray; 1.99 A; A/B/C/D/E/F/G/O=1-335.
DR   PDB; 4WNI; X-ray; 2.30 A; A/B/C/O=1-335.
DR   PDBsum; 1U8F; -.
DR   PDBsum; 1ZNQ; -.
DR   PDBsum; 2FEH; -.
DR   PDBsum; 3GPD; -.
DR   PDBsum; 4WNC; -.
DR   PDBsum; 4WNI; -.
DR   ProteinModelPortal; P04406; -.
DR   SMR; P04406; -.
DR   BioGrid; 108868; 202.
DR   DIP; DIP-32521N; -.
DR   IntAct; P04406; 94.
DR   MINT; MINT-1150338; -.
DR   STRING; 9606.ENSP00000229239; -.
DR   BindingDB; P04406; -.
DR   ChEMBL; CHEMBL2284; -.
DR   DrugBank; DB07347; 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.
DR   DrugBank; DB02059; Adenosine-5-Diphosphoribose.
DR   DrugBank; DB00157; NADH.
DR   DrugBank; DB03893; Thionicotinamide-Adenine-Dinucleotide.
DR   iPTMnet; P04406; -.
DR   PhosphoSitePlus; P04406; -.
DR   SwissPalm; P04406; -.
DR   BioMuta; GAPDH; -.
DR   DMDM; 120649; -.
DR   DOSAC-COBS-2DPAGE; P04406; -.
DR   OGP; P04406; -.
DR   REPRODUCTION-2DPAGE; IPI00219018; -.
DR   REPRODUCTION-2DPAGE; P04406; -.
DR   SWISS-2DPAGE; P04406; -.
DR   UCD-2DPAGE; P04406; -.
DR   EPD; P04406; -.
DR   PaxDb; P04406; -.
DR   PeptideAtlas; P04406; -.
DR   PRIDE; P04406; -.
DR   TopDownProteomics; P04406-1; -. [P04406-1]
DR   DNASU; 2597; -.
DR   Ensembl; ENST00000229239; ENSP00000229239; ENSG00000111640. [P04406-1]
DR   Ensembl; ENST00000396858; ENSP00000380067; ENSG00000111640. [P04406-2]
DR   Ensembl; ENST00000396859; ENSP00000380068; ENSG00000111640. [P04406-1]
DR   Ensembl; ENST00000396861; ENSP00000380070; ENSG00000111640. [P04406-1]
DR   Ensembl; ENST00000619601; ENSP00000478864; ENSG00000111640. [P04406-2]
DR   GeneID; 2597; -.
DR   KEGG; hsa:2597; -.
DR   UCSC; uc031qfw.3; human. [P04406-1]
DR   CTD; 2597; -.
DR   DisGeNET; 2597; -.
DR   GeneCards; GAPDH; -.
DR   H-InvDB; HIX0000949; -.
DR   H-InvDB; HIX0024996; -.
DR   HGNC; HGNC:4141; GAPDH.
DR   HPA; CAB005197; -.
DR   HPA; CAB016392; -.
DR   HPA; HPA040067; -.
DR   HPA; HPA061280; -.
DR   MIM; 138400; gene.
DR   neXtProt; NX_P04406; -.
DR   OpenTargets; ENSG00000111640; -.
DR   PharmGKB; PA28554; -.
DR   eggNOG; KOG0657; Eukaryota.
DR   eggNOG; COG0057; LUCA.
DR   GeneTree; ENSGT00760000119172; -.
DR   HOGENOM; HOG000071678; -.
DR   HOVERGEN; HBG000227; -.
DR   InParanoid; P04406; -.
DR   KO; K00134; -.
DR   OMA; KWGEVGA; -.
DR   OrthoDB; EOG091G0B1Y; -.
DR   PhylomeDB; P04406; -.
DR   TreeFam; TF300533; -.
DR   BioCyc; MetaCyc:HS03433-MONOMER; -.
DR   BRENDA; 1.2.1.12; 2681.
DR   Reactome; R-HSA-70171; Glycolysis.
DR   Reactome; R-HSA-70263; Gluconeogenesis.
DR   SABIO-RK; P04406; -.
DR   UniPathway; UPA00109; UER00184.
DR   ChiTaRS; GAPDH; human.
DR   EvolutionaryTrace; P04406; -.
DR   GeneWiki; Glyceraldehyde_3-phosphate_dehydrogenase; -.
DR   GenomeRNAi; 2597; -.
DR   PRO; PR:P04406; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000111640; -.
DR   CleanEx; HS_GAPDH; -.
DR   ExpressionAtlas; P04406; baseline and differential.
DR   Genevisible; P04406; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:CAFA.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0031012; C:extracellular matrix; IDA:BHF-UCL.
DR   GO; GO:0097452; C:GAIT complex; IDA:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0030529; C:intracellular ribonucleoprotein complex; IDA:UniProtKB.
DR   GO; GO:0005811; C:lipid particle; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0015630; C:microtubule cytoskeleton; ISS:UniProtKB.
DR   GO; GO:0031965; C:nuclear membrane; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0031982; C:vesicle; IDA:UniProtKB.
DR   GO; GO:0097718; F:disordered domain specific binding; IPI:CAFA.
DR   GO; GO:0004365; F:glyceraldehyde-3-phosphate dehydrogenase (NAD+) (phosphorylating) activity; EXP:Reactome.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0008017; F:microtubule binding; ISS:UniProtKB.
DR   GO; GO:0051287; F:NAD binding; IEA:InterPro.
DR   GO; GO:0050661; F:NADP binding; IEA:InterPro.
DR   GO; GO:0035605; F:peptidyl-cysteine S-nitrosylase activity; ISS:UniProtKB.
DR   GO; GO:0061621; P:canonical glycolysis; TAS:Reactome.
DR   GO; GO:0071346; P:cellular response to interferon-gamma; IDA:UniProtKB.
DR   GO; GO:0006094; P:gluconeogenesis; TAS:Reactome.
DR   GO; GO:0000226; P:microtubule cytoskeleton organization; ISS:UniProtKB.
DR   GO; GO:0017148; P:negative regulation of translation; IDA:UniProtKB.
DR   GO; GO:0051402; P:neuron apoptotic process; ISS:UniProtKB.
DR   GO; GO:0035606; P:peptidyl-cysteine S-trans-nitrosylation; ISS:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; ISS:UniProtKB.
DR   GO; GO:0016241; P:regulation of macroautophagy; TAS:ParkinsonsUK-UCL.
DR   InterPro; IPR020831; GlycerAld/Erythrose_P_DH.
DR   InterPro; IPR020830; GlycerAld_3-P_DH_AS.
DR   InterPro; IPR020829; GlycerAld_3-P_DH_cat.
DR   InterPro; IPR020828; GlycerAld_3-P_DH_NAD(P)-bd.
DR   InterPro; IPR006424; Glyceraldehyde-3-P_DH_1.
DR   InterPro; IPR016040; NAD(P)-bd_dom.
DR   PANTHER; PTHR10836; PTHR10836; 1.
DR   Pfam; PF02800; Gp_dh_C; 1.
DR   Pfam; PF00044; Gp_dh_N; 1.
DR   PIRSF; PIRSF000149; GAP_DH; 1.
DR   PRINTS; PR00078; G3PDHDRGNASE.
DR   SMART; SM00846; Gp_dh_N; 1.
DR   SUPFAM; SSF51735; SSF51735; 1.
DR   TIGRFAMs; TIGR01534; GAPDH-I; 1.
DR   PROSITE; PS00071; GAPDH; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ADP-ribosylation; Alternative splicing;
KW   Apoptosis; Complete proteome; Cytoplasm; Cytoskeleton;
KW   Direct protein sequencing; Glycolysis; Membrane; Methylation; NAD;
KW   Nucleus; Oxidation; Oxidoreductase; Phosphoprotein; Polymorphism;
KW   Reference proteome; S-nitrosylation; Transferase;
KW   Translation regulation; Ubl conjugation.
FT   INIT_MET      1      1       Removed. {ECO:0000269|PubMed:12665801,
FT                                ECO:0000269|Ref.19}.
FT   CHAIN         2    335       Glyceraldehyde-3-phosphate dehydrogenase.
FT                                /FTId=PRO_0000145486.
FT   NP_BIND      13     14       NAD. {ECO:0000269|PubMed:16239728,
FT                                ECO:0000269|PubMed:16510976}.
FT   REGION        2    148       Interaction with WARS.
FT                                {ECO:0000269|PubMed:15628863}.
FT   REGION      151    153       Glyceraldehyde 3-phosphate binding.
FT                                {ECO:0000250}.
FT   REGION      211    212       Glyceraldehyde 3-phosphate binding.
FT                                {ECO:0000250}.
FT   MOTIF       245    250       [IL]-x-C-x-x-[DE] motif.
FT                                {ECO:0000305|PubMed:25417112}.
FT   ACT_SITE    152    152       Nucleophile.
FT   BINDING      35     35       NAD. {ECO:0000269|PubMed:16239728,
FT                                ECO:0000269|PubMed:16510976}.
FT   BINDING      80     80       NAD; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:16239728,
FT                                ECO:0000269|PubMed:16510976}.
FT   BINDING     122    122       NAD. {ECO:0000269|PubMed:16239728,
FT                                ECO:0000269|PubMed:16510976}.
FT   BINDING     182    182       Glyceraldehyde 3-phosphate.
FT                                {ECO:0000250}.
FT   BINDING     234    234       Glyceraldehyde 3-phosphate.
FT                                {ECO:0000250}.
FT   BINDING     316    316       NAD. {ECO:0000269|PubMed:16239728,
FT                                ECO:0000269|PubMed:16510976}.
FT   SITE        179    179       Activates thiol group during catalysis.
FT   MOD_RES       5      5       N6,N6-dimethyllysine.
FT                                {ECO:0000269|PubMed:18183946}.
FT   MOD_RES       9      9       Deamidated asparagine.
FT                                {ECO:0000269|PubMed:18183946}.
FT   MOD_RES      42     42       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:15592455}.
FT   MOD_RES      46     46       Methionine sulfoxide; in vitro.
FT                                {ECO:0000305|PubMed:25086035}.
FT   MOD_RES      61     61       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES      64     64       Deamidated asparagine.
FT                                {ECO:0000269|PubMed:18183946}.
FT   MOD_RES      66     66       N6,N6-dimethyllysine.
FT                                {ECO:0000269|PubMed:18183946}.
FT   MOD_RES      70     70       Deamidated asparagine.
FT                                {ECO:0000269|PubMed:18183946}.
FT   MOD_RES      75     75       Phosphothreonine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000269|PubMed:18183946}.
FT   MOD_RES      83     83       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     122    122       Phosphoserine.
FT                                {ECO:0000269|PubMed:18183946}.
FT   MOD_RES     148    148       Phosphoserine.
FT                                {ECO:0000269|PubMed:18183946}.
FT   MOD_RES     149    149       Deamidated asparagine.
FT                                {ECO:0000269|PubMed:18183946}.
FT   MOD_RES     151    151       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     152    152       ADP-ribosylcysteine; by autocatalysis; in
FT                                irreversibly inhibited form.
FT                                {ECO:0000250}.
FT   MOD_RES     152    152       Cysteine persulfide. {ECO:0000250}.
FT   MOD_RES     152    152       S-nitrosocysteine; in reversibly
FT                                inhibited form.
FT                                {ECO:0000250|UniProtKB:P04797}.
FT   MOD_RES     153    153       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     155    155       Deamidated asparagine.
FT                                {ECO:0000269|PubMed:18183946}.
FT   MOD_RES     177    177       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     182    182       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     184    184       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     194    194       N6,N6-dimethyllysine; alternate.
FT                                {ECO:0000269|PubMed:18183946}.
FT   MOD_RES     194    194       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     194    194       N6-malonyllysine; alternate.
FT                                {ECO:0000269|PubMed:21908771}.
FT   MOD_RES     211    211       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     215    215       N6,N6-dimethyllysine; alternate.
FT                                {ECO:0000269|PubMed:18183946}.
FT   MOD_RES     215    215       N6-malonyllysine; alternate.
FT                                {ECO:0000269|PubMed:21908771}.
FT   MOD_RES     219    219       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     225    225       Deamidated asparagine.
FT                                {ECO:0000269|PubMed:18183946}.
FT   MOD_RES     227    227       N6,N6-dimethyllysine; alternate.
FT                                {ECO:0000269|PubMed:18183946}.
FT   MOD_RES     227    227       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     229    229       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:18183946}.
FT   MOD_RES     237    237       Phosphothreonine.
FT                                {ECO:0000269|PubMed:18183946}.
FT   MOD_RES     241    241       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     247    247       S-nitrosocysteine.
FT                                {ECO:0000269|PubMed:22771119,
FT                                ECO:0000269|PubMed:25417112}.
FT   MOD_RES     254    254       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     260    260       N6,N6-dimethyllysine.
FT                                {ECO:0000269|PubMed:18183946}.
FT   MOD_RES     263    263       N6,N6-dimethyllysine.
FT                                {ECO:0000269|PubMed:18183946}.
FT   MOD_RES     312    312       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000269|PubMed:18183946}.
FT   MOD_RES     316    316       Deamidated asparagine.
FT                                {ECO:0000269|PubMed:18183946}.
FT   MOD_RES     333    333       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     334    334       N6,N6-dimethyllysine.
FT                                {ECO:0000269|PubMed:18183946}.
FT   VAR_SEQ       1     42       Missing (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_047289.
FT   VARIANT      22     22       A -> G (in dbSNP:rs45541435).
FT                                {ECO:0000269|Ref.12}.
FT                                /FTId=VAR_018889.
FT   VARIANT     251    251       K -> N (in dbSNP:rs1062429).
FT                                /FTId=VAR_049218.
FT   MUTAGEN      46     46       M->L: Drastic reduction of the extent and
FT                                significant prolongation of the lag phase
FT                                of free radical-induced aggregation.
FT                                {ECO:0000269|PubMed:25086035}.
FT   MUTAGEN     105    105       M->L: Increased resistance to free
FT                                radical-induced aggregation.
FT                                {ECO:0000269|PubMed:25086035}.
FT   MUTAGEN     152    152       C->S: Markedly reduced glycolytic
FT                                activity; when associated with S-156 and
FT                                S-247. Forms free radical-induced
FT                                aggregates, but to a lesser extent than
FT                                wild-type protein; when associated with
FT                                S-156 and S-247.
FT                                {ECO:0000269|PubMed:25086035}.
FT   MUTAGEN     156    156       C->S: Markedly reduced glycolytic
FT                                activity; when associated with S-152 and
FT                                S-247. Forms free radical-induced
FT                                aggregates, but to a lesser extent than
FT                                wild-type protein; when associated with
FT                                S-156 and S-247.
FT                                {ECO:0000269|PubMed:25086035}.
FT   MUTAGEN     196    196       W->F: Increased free radical-induced
FT                                aggregation.
FT                                {ECO:0000269|PubMed:25086035}.
FT   MUTAGEN     245    245       L->M: Inhibits S-nitrosylation of Cys-
FT                                247; when associated with M-250.
FT                                {ECO:0000269|PubMed:25417112}.
FT   MUTAGEN     247    247       C->S: Markedly reduced glycolytic
FT                                activity; when associated with S-152 and
FT                                S-156. Forms free radical-induced
FT                                aggregates, but to a lesser extent than
FT                                wild-type protein; when associated with
FT                                S-156 and S-247.
FT                                {ECO:0000269|PubMed:25086035}.
FT   MUTAGEN     250    250       E->M: Inhibits S-nitrosylation of Cys-
FT                                247; when associated with M-245.
FT                                {ECO:0000269|PubMed:25417112}.
FT   MUTAGEN     320    320       Y->F: No effect on free radical-induced
FT                                aggregation.
FT                                {ECO:0000269|PubMed:25086035}.
FT   CONFLICT    225    225       N -> D (in Ref. 2; CAA25833).
FT                                {ECO:0000305}.
FT   STRAND        5      9       {ECO:0000244|PDB:1U8F}.
FT   HELIX        13     25       {ECO:0000244|PDB:1U8F}.
FT   STRAND       27     34       {ECO:0000244|PDB:1U8F}.
FT   STRAND       36     38       {ECO:0000244|PDB:1U8F}.
FT   HELIX        40     48       {ECO:0000244|PDB:1U8F}.
FT   TURN         51     53       {ECO:0000244|PDB:1U8F}.
FT   STRAND       60     63       {ECO:0000244|PDB:1U8F}.
FT   STRAND       66     69       {ECO:0000244|PDB:1U8F}.
FT   STRAND       72     77       {ECO:0000244|PDB:1U8F}.
FT   HELIX        82     84       {ECO:0000244|PDB:1U8F}.
FT   TURN         87     91       {ECO:0000244|PDB:1U8F}.
FT   STRAND       94     97       {ECO:0000244|PDB:1U8F}.
FT   STRAND       99    101       {ECO:0000244|PDB:1U8F}.
FT   HELIX       105    108       {ECO:0000244|PDB:1U8F}.
FT   HELIX       109    114       {ECO:0000244|PDB:1U8F}.
FT   STRAND      117    123       {ECO:0000244|PDB:1U8F}.
FT   STRAND      126    128       {ECO:0000244|PDB:1U8F}.
FT   TURN        133    135       {ECO:0000244|PDB:1U8F}.
FT   HELIX       137    139       {ECO:0000244|PDB:1U8F}.
FT   STRAND      145    148       {ECO:0000244|PDB:1U8F}.
FT   HELIX       152    168       {ECO:0000244|PDB:1U8F}.
FT   STRAND      170    180       {ECO:0000244|PDB:1U8F}.
FT   STRAND      185    189       {ECO:0000244|PDB:1U8F}.
FT   HELIX       196    199       {ECO:0000244|PDB:1U8F}.
FT   TURN        202    204       {ECO:0000244|PDB:1U8F}.
FT   STRAND      207    210       {ECO:0000244|PDB:1U8F}.
FT   TURN        213    216       {ECO:0000244|PDB:1U8F}.
FT   HELIX       217    220       {ECO:0000244|PDB:1U8F}.
FT   HELIX       222    224       {ECO:0000244|PDB:1U8F}.
FT   STRAND      227    236       {ECO:0000244|PDB:1U8F}.
FT   STRAND      241    251       {ECO:0000244|PDB:1U8F}.
FT   HELIX       255    267       {ECO:0000244|PDB:1U8F}.
FT   TURN        268    273       {ECO:0000244|PDB:1U8F}.
FT   STRAND      274    277       {ECO:0000244|PDB:1U8F}.
FT   HELIX       283    286       {ECO:0000244|PDB:1U8F}.
FT   STRAND      292    296       {ECO:0000244|PDB:1U8F}.
FT   TURN        297    299       {ECO:0000244|PDB:1U8F}.
FT   STRAND      301    304       {ECO:0000244|PDB:1U8F}.
FT   STRAND      307    314       {ECO:0000244|PDB:1U8F}.
FT   HELIX       318    333       {ECO:0000244|PDB:1U8F}.
SQ   SEQUENCE   335 AA;  36053 MW;  C9C135E8AE3E8744 CRC64;
     MGKVKVGVNG FGRIGRLVTR AAFNSGKVDI VAINDPFIDL NYMVYMFQYD STHGKFHGTV
     KAENGKLVIN GNPITIFQER DPSKIKWGDA GAEYVVESTG VFTTMEKAGA HLQGGAKRVI
     ISAPSADAPM FVMGVNHEKY DNSLKIISNA SCTTNCLAPL AKVIHDNFGI VEGLMTTVHA
     ITATQKTVDG PSGKLWRDGR GALQNIIPAS TGAAKAVGKV IPELNGKLTG MAFRVPTANV
     SVVDLTCRLE KPAKYDDIKK VVKQASEGPL KGILGYTEHQ VVSSDFNSDT HSSTFDAGAG
     IALNDHFVKL ISWYDNEFGY SNRVVDLMAH MASKE
//
